Please use this identifier to cite or link to this item: doi:10.22028/D291-36716
Title: IgE is associated with exacerbations and lung function decline in COPD
Author(s): Lommatzsch, Marek
Speer, Timotheus
Herr, Christian
Jörres, Rudolf A.
Watz, Henrik
Müller, Achim
Welte, Tobias
Vogelmeier, Claus F.
Bals, Robert
Language: English
Title: Respiratory Research
Volume: 23
Issue: 1
Publisher/Platform: BMC
Year of Publication: 2022
Free key words: COPD
IgE
Exacerbations
Lung function decline
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: Background: Both allergen-specifc IgE and total IgE in serum play a major role in asthma. However, the role of IgE in chronic obstructive pulmonary disease (COPD) is poorly understood. It was the aim of this study to systematically analyze the relationship between serum IgE levels and disease characteristics in large COPD cohorts. Methods: COSYCONET is a comprehensively characterized cohort of patients with COPD: total IgE and IgE specifc to common aeroallergens were measured in serum of 2280 patients, and related to clinical characteristics of the patients. WISDOM is another large COPD population (2477 patients): this database contains the information whether total IgE in serum was elevated (≥100 IU/l) or normal in patients with COPD. Results: Both in COSYCONET and WISDOM, total IgE was elevated (≥100 IU/l) in>30% of the patients, higher in men than in women, and higher in currently than in not currently smoking men. In COSYCONET, total IgE was elevated in patients with a history of asthma and/or allergies. Men with at least one exacerbation in the last 12 months (50.6% of all men in COSYCONET) had higher median total IgE (71.3 IU/l) than men without exacerbations (48.3 IU/l): this diference was also observed in the subgroups of not currently smoking men and of men without a history of asthma. Surprisingly, a history of exacerbations did not impact on total IgE in women with COPD. Patients in the highest ter tiles of total IgE (>91.5 IU/ml, adjusted OR: 1.62, 95% CI 1.12–2.34) or allergen-specifc IgE (>0.19 IU/ml, adjusted OR: 2.15, 95% CI 1.32–3.51) were at risk of lung function decline (adjusted by: age, gender, body mass index, initial lung function, smoking status, history of asthma, history of allergy). Conclusion: These data suggest that IgE may play a role in specifc COPD subgroups. Clinical trials using antibodies targeting the IgE pathway (such as omalizumab), especially in men with recurrent exacerbations and elevated serum IgE, could elucidate potential therapeutic implications of our observations.
DOI of the first publication: 10.1186/s12931-021-01847-0
URL of the first publication: https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-021-01847-0
Link to this record: urn:nbn:de:bsz:291--ds-367166
hdl:20.500.11880/33361
http://dx.doi.org/10.22028/D291-36716
ISSN: 1465-993X
Date of registration: 8-Jul-2022
Description of the related object: Supplementary Information
Related object: https://static-content.springer.com/esm/art%3A10.1186%2Fs12931-021-01847-0/MediaObjects/12931_2021_1847_MOESM1_ESM.pdf
Faculty: M - Medizinische Fakultät
Department: M - Innere Medizin
Professorship: M - Prof. Dr. Robert Bals
M - Dr. med. Dr. sc.nat. Timo Speer
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Files for this record:
File Description SizeFormat 
s12931-021-01847-0.pdf1,49 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons